CL2008002566A1 - Compuestos antagonistas de la tsh derivados de tetrahidroquinolina, composicion farmaceutica, util para tratar una enfermedad o condicion seleccionada de hipertiroidismo, enfermedad de graves, oftalmopatia de graves, dermopatia pretibial asociada a graves, bocio nodular y cancer de tiroides. - Google Patents

Compuestos antagonistas de la tsh derivados de tetrahidroquinolina, composicion farmaceutica, util para tratar una enfermedad o condicion seleccionada de hipertiroidismo, enfermedad de graves, oftalmopatia de graves, dermopatia pretibial asociada a graves, bocio nodular y cancer de tiroides.

Info

Publication number
CL2008002566A1
CL2008002566A1 CL2008002566A CL2008002566A CL2008002566A1 CL 2008002566 A1 CL2008002566 A1 CL 2008002566A1 CL 2008002566 A CL2008002566 A CL 2008002566A CL 2008002566 A CL2008002566 A CL 2008002566A CL 2008002566 A1 CL2008002566 A1 CL 2008002566A1
Authority
CL
Chile
Prior art keywords
disease
grave
graves
hyperthyroidism
tetrahydroquinoline
Prior art date
Application number
CL2008002566A
Other languages
English (en)
Inventor
Willem Frederik Johan Karstens
Paolo Giovanni Martino Conti
Cornelis Marius Timmers
Ralf Plate
Original Assignee
N V Organon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by N V Organon filed Critical N V Organon
Publication of CL2008002566A1 publication Critical patent/CL2008002566A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Compuestos antagonistas de la TSH derivados de tetrahidroquinolina, composición farmacéutica, útil para tratar una enfermedad o condición seleccionada de hipertiroidismo, enfermedad de graves, oftalmopatía de graves, dermopatía pretibial asociada a graves, bocio nodular y cáncer de tiroides.
CL2008002566A 2007-08-31 2008-08-29 Compuestos antagonistas de la tsh derivados de tetrahidroquinolina, composicion farmaceutica, util para tratar una enfermedad o condicion seleccionada de hipertiroidismo, enfermedad de graves, oftalmopatia de graves, dermopatia pretibial asociada a graves, bocio nodular y cancer de tiroides. CL2008002566A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07115368 2007-08-31
EP08150398 2008-01-18

Publications (1)

Publication Number Publication Date
CL2008002566A1 true CL2008002566A1 (es) 2009-01-02

Family

ID=40387927

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008002566A CL2008002566A1 (es) 2007-08-31 2008-08-29 Compuestos antagonistas de la tsh derivados de tetrahidroquinolina, composicion farmaceutica, util para tratar una enfermedad o condicion seleccionada de hipertiroidismo, enfermedad de graves, oftalmopatia de graves, dermopatia pretibial asociada a graves, bocio nodular y cancer de tiroides.

Country Status (13)

Country Link
US (1) US9174940B2 (es)
EP (1) EP2197445B1 (es)
JP (1) JP5467044B2 (es)
KR (1) KR20100063105A (es)
CN (1) CN101790376B (es)
AR (1) AR068065A1 (es)
AU (1) AU2008292134B2 (es)
CA (1) CA2695503A1 (es)
CL (1) CL2008002566A1 (es)
MX (1) MX2010002192A (es)
PE (1) PE20090955A1 (es)
TW (1) TW200918058A (es)
WO (1) WO2009027482A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090124651A1 (en) 2007-08-31 2009-05-14 H. Lundbeck A/S Catecholamine derivatives and prodrugs thereof
PL2753928T3 (pl) * 2011-09-09 2018-07-31 Quidel Corporation Kompozycje i sposoby wykrywania autoprzeciwciał
KR102394518B1 (ko) * 2014-01-09 2022-05-06 오리온 코포레이션 브로모도메인 억제제로서의 비사이클릭 헤테로사이클릭 유도체
KR101686881B1 (ko) * 2014-07-25 2016-12-20 연세대학교 산학협력단 스타틴을 포함하는 갑상선 안병증의 예방 또는 치료용 약제학적 조성물
TW202408996A (zh) * 2022-06-30 2024-03-01 日商橘生藥品工業股份有限公司 3,4-二氫喹啉-2(1h)-酮化合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4237430C1 (de) * 1992-11-05 1994-03-17 Henning Berlin Gmbh Aufgereinigtes TSH-Präparat, Verfahren zu seiner Herstellung und seine Verwendung zur Herstellung von TSH-Tracern für TSH-Rezeptorassays und in TSH-Rezeptorassays
JPH0789991A (ja) * 1993-09-28 1995-04-04 Mitsubishi Chem Corp 新規なポリペプチドおよびそれを用いるｔｓｈ受容体抗体の測定法
JPH09140386A (ja) * 1995-11-22 1997-06-03 Eiken Chem Co Ltd 甲状腺機能を刺激する活性を持つ抗体
CA2452606C (en) * 2001-07-02 2011-09-13 Akzo Nobel N.V. Tetrahydroquinoline derivatives
TWI322012B (en) * 2002-12-20 2010-03-21 Organon Nv Tetrahydroquinoline derivatives
TWI306855B (en) * 2002-12-20 2009-03-01 Organon Nv Tetrahydroquinoline derivatives
US7560528B2 (en) 2003-06-20 2009-07-14 Efthimios Ippikoglou Method of producing recombinant DNA molecules

Also Published As

Publication number Publication date
JP5467044B2 (ja) 2014-04-09
JP2010536934A (ja) 2010-12-02
WO2009027482A3 (en) 2009-05-28
EP2197445A2 (en) 2010-06-23
EP2197445B1 (en) 2017-04-19
MX2010002192A (es) 2010-03-17
WO2009027482A2 (en) 2009-03-05
US9174940B2 (en) 2015-11-03
CN101790376A (zh) 2010-07-28
TW200918058A (en) 2009-05-01
US20110172267A1 (en) 2011-07-14
AR068065A1 (es) 2009-11-04
AU2008292134A1 (en) 2009-03-05
CN101790376B (zh) 2013-06-12
KR20100063105A (ko) 2010-06-10
PE20090955A1 (es) 2009-07-23
AU2008292134B2 (en) 2013-06-13
CA2695503A1 (en) 2009-03-05

Similar Documents

Publication Publication Date Title
EA201290919A1 (ru) Индазольные соединения и их применение
BRPI0908635B8 (pt) composto e/ou um sal farmaceuticamente aceitável do mesmo e composição farmacêutica
UA122324C2 (uk) Терапевтично активні сполуки і способи їх застосування
EA200870415A1 (ru) Хиназолины для ингибирования pdk 1
EA201290026A1 (ru) Способ лечения пациента, имеющего риск развития язвы, связанной с приемом нестероидных противовоспалительных средств (nsaid)
BR112012026767A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para tratar ou previnir distúrbios, e, uso de um composto ou sal
TR201900306T4 (tr) Mek inhibitörlerini kullanma yöntemleri.
BRPI0909768A2 (pt) composto, composição farmacêutica, método para o tratamento ou prevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto""composto, composição farmacêutica, método para o tratamento ou orevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto
EA201390843A1 (ru) Применение агониста toll-подобного рецептора для лечения рака
JO2848B1 (en) Organic compounds
BRPI0816382A2 (pt) Composto, composição, e, métodos para ativar a guanilato ciclase solúvel e para tratar ou previnir doenças
EA201200473A1 (ru) Замещенные (гетероарилметил)тиогидантоины
EA201001847A1 (ru) Соединения и композиции, применяемые для лечения малярии
NO20091661L (no) Anvendelse av pegylert IL-10 for a behandle kreft
MX338338B (es) Composiciones y metodos utiles para el tratamiento de enfermedades respiratorias.
EA200970935A1 (ru) Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
AR077014A1 (es) Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
MY150602A (en) Subtituted-quinoxaline-type piperidine compounds and the uses thereof
MX2009013815A (es) Compuestos de quinazolinona y metodos de uso para los mismos.
CL2008002558A1 (es) Compuestos derivados de catecolamina sustituidas, composicion farmaceutica, util para tratar parkinson, huntington, psicosis, impotencia e insuficiencia renal, entre otras enfermedades.
GT201200164A (es) "nuevos compuestos de espiropiperidina"
EA201201324A1 (ru) Профилактика колоректального и желудочно-кишечного рака
CL2008002566A1 (es) Compuestos antagonistas de la tsh derivados de tetrahidroquinolina, composicion farmaceutica, util para tratar una enfermedad o condicion seleccionada de hipertiroidismo, enfermedad de graves, oftalmopatia de graves, dermopatia pretibial asociada a graves, bocio nodular y cancer de tiroides.
DOP2010000302A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida
CY1115081T1 (el) Νεο εκχυλισμα απο γαϊδουραγκαθο, μεθοδος για την παρασκευη και η χρηση του